Format

Send to

Choose Destination
J Alzheimers Dis. 2016;51(1):15-9. doi: 10.3233/JAD-150915.

Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study.

Author information

1
Abarbanel Mental Health Center, Bat-Yam, Israel and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
2
Department of Psychology, Bar-Ilan University, Ramat-Gan, Israel.

Abstract

BACKGROUND:

Tetrahydrocannabinol (THC) is a potential treatment for Alzheimer's disease (AD).

OBJECTIVE:

To measure efficacy and safety of medical cannabis oil (MCO) containing THC as an add-on to pharmacotherapy, in relieving behavioral and psychological symptoms of dementia (BPSD).

METHODS:

Eleven AD patients were recruited to an open label, 4 weeks, prospective trial.

RESULTS:

Ten patients completed the trial. Significant reduction in CGI severity score (6.5 to 5.7; p <  0.01) and NPI score were recorded (44.4 to 12.8; p <  0.01). NPI domains of significant decrease were: Delusions, agitation/aggression, irritability, apathy, sleep and caregiver distress.

CONCLUSION:

Adding MCO to AD patients' pharmacotherapy is safe and a promising treatment option.

KEYWORDS:

Alzheimer’s disease; behavioral and psychological symptoms of dementia; cannabis; tetrahydrocannabinol

PMID:
26757043
DOI:
10.3233/JAD-150915
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for IOS Press
Loading ...
Support Center